“The initiation of our Phase III program marks a significant milestone in the development of linaprazan glurate. Current preclinical and clinical data have demonstrated strong potential, and this study will be essential in evaluating the efficacy and safety of linaprazan glurate in a broader patient population. We are excited to have started the study and look forward to the insights it will generate,” says Kajsa Larsson, Chief Medical Officer at Cinclus Pharma.

“Screening the first patient in our Phase III program represents an important achievement for Cinclus Pharma underscoring our commitment to advancing therapies for acid-related disorders, and marking our transition into a late-stage clinical company. We believe linaprazan glurate could set a new standard in this treatment landscape thanks to its unique 24hr acid control. With full funding beyond the topline results next year, we are well-positioned to advance the program,” says Christer Ahlberg, CEO, Cinclus Pharma.